文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

库普弗细胞通过白细胞介素-1β依赖性抑制过氧化物酶体增殖物激活受体α活性促进肝脂肪变性。

Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity.

机构信息

Nutrigenomics Consortium, TI Food and Nutrition, Wageningen, The Netherlands.

出版信息

Hepatology. 2010 Feb;51(2):511-22. doi: 10.1002/hep.23337.


DOI:10.1002/hep.23337
PMID:20054868
Abstract

UNLABELLED: Kupffer cells have been implicated in the pathogenesis of various liver diseases. However, their involvement in metabolic disorders of the liver, including fatty liver disease, remains unclear. The present study sought to determine the impact of Kupffer cells on hepatic triglyceride storage and to explore the possible mechanisms involved. To that end, C57Bl/6 mice rendered obese and steatotic by chronic high-fat feeding were treated for 1 week with clodronate liposomes, which cause depletion of Kupffer cells. Loss of expression of marker genes Cd68, F4/80, and Clec4f, and loss of Cd68 immunostaining verified almost complete removal of Kupffer cells from the liver. Also, expression of complement components C1, the chemokine (C-C motif) ligand 6 (Ccl6), and cytokines interleukin-15 (IL-15) and IL-1beta were markedly reduced. Importantly, Kupffer cell depletion significantly decreased liver triglyceride and glucosylceramide levels concurrent with increased expression of genes involved in fatty acid oxidation including peroxisome proliferator-activated receptor alpha (PPARalpha), carnitine palmitoyltransferase 1A (Cpt1alpha), and fatty acid transport protein 2 (Fatp2). Treatment of mice with IL-1beta decreased expression of PPARalpha and its target genes, which was confirmed in primary hepatocytes. Consistent with these data, IL-1beta suppressed human and mouse PPARalpha promoter activity. Suppression of PPARalpha promoter activity was recapitulated by overexpression of nuclear factor kappaB (NF-kappaB) subunit p50 and p65, and was abolished upon deletion of putative NF-kappaB binding sites. Finally, IL-1beta and NF-kappaB interfered with the ability of PPARalpha to activate gene transcription. CONCLUSION: Our data point toward important cross-talk between Kupffer cells and hepatocytes in the regulation of hepatic triglyceride storage. The effect of Kupffer cells on liver triglycerides are at least partially mediated by IL-1beta, which suppresses PPARalpha expression and activity.

摘要

未注明:库普弗细胞(Kupffer cells)已被牵涉到各种肝脏疾病的发病机制中。然而,它们在包括脂肪肝疾病在内的肝脏代谢紊乱中的作用仍不清楚。本研究旨在确定库普弗细胞对肝甘油三酯储存的影响,并探讨可能涉及的机制。为此,用氯膦酸盐脂质体处理慢性高脂肪喂养导致肥胖和脂肪变性的 C57Bl/6 小鼠 1 周,氯膦酸盐脂质体可导致库普弗细胞耗竭。标志物基因 Cd68、F4/80 和 Clec4f 的表达缺失以及 Cd68 免疫染色的缺失证实了库普弗细胞几乎从肝脏中完全去除。此外,补体成分 C1、趋化因子(C-C 基序)配体 6(Ccl6)和细胞因子白细胞介素-15(IL-15)和白细胞介素-1β(IL-1β)的表达明显减少。重要的是,库普弗细胞耗竭显著降低了肝甘油三酯和葡糖脑苷脂水平,同时参与脂肪酸氧化的基因表达增加,包括过氧化物酶体增殖物激活受体α(PPARα)、肉碱棕榈酰转移酶 1A(Cpt1α)和脂肪酸转运蛋白 2(Fatp2)。用白细胞介素-1β(IL-1β)处理小鼠会降低 PPARα及其靶基因的表达,这在原代肝细胞中得到了证实。与这些数据一致,IL-1β抑制了人源和鼠源 PPARα 启动子活性。核因子 kappaB(NF-kappaB)亚基 p50 和 p65 的过表达可再现 PPARα 启动子活性的抑制,而潜在的 NF-kappaB 结合位点的缺失可消除这种抑制。最后,白细胞介素-1β(IL-1β)和 NF-kappaB 干扰了 PPARα激活基因转录的能力。

结论:我们的数据表明,库普弗细胞和肝细胞之间在调节肝甘油三酯储存方面存在重要的交叉对话。库普弗细胞对肝脏甘油三酯的影响至少部分是由白细胞介素-1β(IL-1β)介导的,白细胞介素-1β(IL-1β)抑制 PPARα 的表达和活性。

相似文献

[1]
Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity.

Hepatology. 2010-2

[2]
Kupffer cells suppress perfluorononanoic acid-induced hepatic peroxisome proliferator-activated receptor α expression by releasing cytokines.

Arch Toxicol. 2012-5-31

[3]
Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice.

Metabolism. 2005-11

[4]
Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.

J Gastroenterol Hepatol. 2008-2

[5]
Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

J Gastroenterol Hepatol. 2012-2

[6]
N-3 long-chain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR-α upregulation and NF-κB DNA binding abrogation.

Mol Nutr Food Res. 2014-6

[7]
Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and -independent pathways.

Am J Physiol Endocrinol Metab. 2011-8-23

[8]
Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.

Arthritis Rheum. 2006-4

[9]
Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.

Obesity (Silver Spring). 2009-10-1

[10]
IL-6 cooperates with peroxisome proliferator-activated receptor-α-ligands to induce liver fatty acid binding protein (LFABP) up-regulation.

Liver Int. 2013-3-28

引用本文的文献

[1]
MASLD: insights on the role of folate in hepatic lipid metabolism.

Front Nutr. 2025-7-16

[2]
CD47-mediated regulation of glucose and lipid metabolism: implications for the pathogenesis of MASLD.

Front Endocrinol (Lausanne). 2025-6-24

[3]
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.

World J Hepatol. 2025-6-27

[4]
Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease.

Front Pharmacol. 2025-6-9

[5]
Mammalian Ste20-like kinase 1 regulates AMPK to mitigate the progression of non-alcoholic fatty liver disease.

Eur J Med Res. 2025-4-17

[6]
Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4/NFκB pathway.

Sci Rep. 2025-3-21

[7]
Targeting Regulation of Macrophage to Treat Metabolic Disease: Role of Phytochemicals.

Cell Prolif. 2025-7

[8]
Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease.

Liver Res. 2021-9-2

[9]
Smad4 deficiency in hepatocytes attenuates NAFLD progression via inhibition of lipogenesis and macrophage polarization.

Cell Death Dis. 2025-1-31

[10]
Exosome-equipped TNF antisense oligodeoxynucleotide or 2-deoxy-D-glucose ameliorated nonalcoholic steatohepatitis by modulating superoxide dismutase 1 in mice.

Redox Biol. 2025-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索